Market closedNon-fractional
Nuvation Bio/NUVB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Ticker
NUVB
Sector
Healthcare
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
New York, United States
Employees
159
Website
www.nuvationbio.com
Nuvation Bio Metrics
BasicAdvanced
$918M
Market cap
-
P/E ratio
-$0.31
EPS
1.42
Beta
-
Dividend rate
Price and volume
Market cap
$918M
Beta
1.42
Financial strength
Current ratio
38.577
Quick ratio
38.146
Long term debt to equity
0.254
Total debt to equity
0.595
Management effectiveness
Return on assets (TTM)
-9.20%
Return on equity (TTM)
-11.15%
Valuation
Price to book
1.36
Price to tangible book (TTM)
1.36
Price to free cash flow (TTM)
-12.535
Growth
Earnings per share change (TTM)
-34.45%
3-year earnings per share growth (CAGR)
-11.34%
What the Analysts think about Nuvation Bio
Analyst Ratings
Majority rating from 6 analysts.
Nuvation Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
7.30%
Profit margin
0.00%
NaN%
Nuvation Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.09
-$0.06
-$0.07
-
Expected
-$0.11
-$0.11
-$0.10
-$0.10
-$0.06
Surprise
-19.52%
-17.93%
-42.77%
-26.93%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $918M as of July 27, 2024.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of July 27, 2024.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Nuvation Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.